Aptamer-assisted isolation and analysis of tumor-derived exosomes in urine and saliva

癌症的有效诊断和预后取决于从低浓度的临床样品中定量测量癌症生物标志物的能力。肿瘤来源的外泌体（TEX）已经成为用于早期癌症检测和抗癌治疗监测的癌症生物标志物的有希望的来源，因为TEX以高浓度携带癌症生物标志物。由于外来体是稳定的膜体，它们保护用作生物标志物的蛋白质和核酸免受唾液和尿液中的降解。此外，与体液中的低丰度生物分子相比，特克斯更容易收集和富集。*在这个项目中，渥太华大学的Berezovski研究小组和加拿大医疗器械公司iNano Medical Incorporated将开发一种诊断设备，用于分析唾液和尿液中的肿瘤源性外泌体。该设备将依赖于DNA适体来捕获和浓缩含有蛋白质和核酸癌症生物标志物的外泌体，并且具有远程表面等离子体极化激元检测的微机电系统将能够定量报告生物标志物。这种基于微芯片的、快速、灵敏和非侵入性的诊断设备将允许进行癌症检测的常规测试，确定疾病的严重程度，从而提供高质量的诊断以指导临床决策和治疗。这项创新的临床诊断技术将加速iNano的产品开发，对加拿大的医疗保健产生积极影响，并提高患者的癌症管理质量。

The effective diagnosis and prognosis of cancer depends on the ability to quantitatively measure cancer biomarkers from clinical samples at low concentrations. Tumor-derived exosomes (TEX) have emerged as a promising source of cancer biomarkers for both early cancer detection and anti-cancer treatment monitoring, since TEX carry the cancer biomarkers at high concentration. Because exosomes are stable membrane bodies, they protect the proteins and nucleic acids used as biomarkers from degradation in saliva and urine. Also, TEX can be more easily collected and enriched compared to low abundance biomolecules in body fluids.****In this project, the Berezovski research team at the University of Ottawa and a Canadian medical device company, iNano Medical Incorporated, will develop a diagnostic device for analysis of tumor-derived exosomes in saliva and urine. The device will rely on DNA aptamers to capture and concentrate the exosomes containing the protein and nucleic acid cancer biomarkers, and a microelectromechanical system with long-range surface plasmon-polariton detection will enable quantitative reporting of the biomarkers. This microchip-based, rapid, sensitive, and non-invasive diagnostic device would allow routine testing for cancer detection, determination of the severity of the disease, thus providing high quality diagnosis to guide clinical decision and treatments. This innovative clinical diagnostic technology will accelerate iNano's product development, positively impact Canadian healthcare, and improve the quality of cancer management for patients.**